Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides': Cellular responses and pharmacodynamic implications

Molecular Pharmacology

Volumn 53, Issue 1, 1998, Pages 97-104

  Schumacher, Christoph ^a   Cioffi, Catherine L ^a   Sharif, Haamid ^a   Haston, William ^a   Monia, Brett P ^b   Wennogle, Lawrence ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CGP 69846A; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RAF PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN METABOLISM; VASCULAR SMOOTH MUSCLE;

EID: 0031913358     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.53.1.97     Document Type: Article

References (35)

1. Bennett CF, Chiang M-Y, Chan H, Shoemaker JEE, and Mirabelli CK (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41:1023-1033.
2. Bogoyevitch MA, Marshall CJ, and Sugden PH (1995) Hypertrophic agonists stimulate the activities of the protein kinases c-Raf and A-Raf in cultured ventricular myocytes. J Biol Chem 270:26303-26310.
3. Cioffi CL, Garay M, Johnston JF, McGraw K, Boggs RT, Hreniuk D, and Monia BP (1997) Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation. Mol Pharmacol 51:383-389.
4. Consigny MP (1995) Pathogenesis of atherosclerosis. Am J Roentgenol 164:553-558.
5. Crooke ST, Lemonidis KM, Neilson L, Griffey R, Lesnik EA, and Monia BP (1995) Kinetic characteristics of Escherichia coli RNAse H1: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem J 312:599-608.
6. Daum G, Eisenmann-Tappe I, Fries H-W, Troppmair J, and Rapp UR (1994) The ins and outs of Raf kinases. Trends Biochem Sci 19:474-480.
7. Davis DJ (1993) The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 268:14553-14556.
8. Gibbons GH and Dzau VJ (1994) The emerging concept of vascular remodeling. N Engl J Med 330:1431-1438.
9. Haudenschild CC (1995) Pathophysiology of reocclusion and restenosis. Fibrinolysis 9:44-47.
10. Jaiswal RK, Moodie SA, Wolfman A, and Landreth GE (1994) The mitogen-activated protein kinase cascade is activated by B-Raf in response to nerve growth factor through interaction with p21ras. Mol Cell Biol 14:6944-6953.
11. Kolch W, Heidecker G, Lloyd P, and Rapp UR (1991) Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature (Lond) 349:426-428.
12. Laird DA, Taylor SJ, Oberst M, and Shalloway D (1995) Raf-1 is activated during mitosis. J Biol Chem 270:26742-26745.
13. Leevers SJ, Paterson HF, and Marshall CJ (1994) Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature (Lond) 369:411-414.
14. Lovric J and Moelling K (1996) Activation of Mil/Raf protein kinases in mitotic cells. Oncogene 12:1109-1116.
15. Marshall CJ (1994) MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Gen Dev 4:82-89.
16. Milligan JF, Matteucci MD, and Martin JC (1993) Current concepts of antisense drug design. J Med Chem 36:1923-1937.
17. Monia BP, Johnston JF, Geiger T, Muller M, and Fabbro D (1996a) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 2:668-675.
18. Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, and Freier SM (1993) Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268:14514-14522.
19. Monia BP, Sasmor H, Johnston JF, Freier SM, Lesnik EA, Muller M, Geiger T, Altmann K-H, Moser H, and Fabbro D (1996b) Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci USA 93:15481-15484.
20. Morishito R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, and Dzau VJ (1993) Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 90:8474-8478.
21. Morishito R, Gibbons GH, Ellison KE, Nakajima M, van der Leyen H, Zhang L, Kaneda Y, Ogihara T, and Dzau VJ (1994) Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest 93: 1458-1464.
22. Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, DeCaprio JA, and Ewen ME (1997) Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature (Lond) 386:177-181.
23. Quelle DE, Ashmun RA, Shurtleff SA, Kato J-Y, Bar-Sagi D, Roussel MF, and Sherr CJ (1993) Overexpression of mouse D-type cyclins accelerates Gl phase in rodent fibroblasts. Genes Dev 7:1559-1571.
24. Robinson CJM, Scott PH, Allan AB, Jess T, Gould GW, and Plevin R (1996) Treatment of vascular smooth muscle cells with antisense phophorothioate oligode-oxynucleotides directed against p42 and p44 mitogen-activated protein kinases abolishes DNA synthesis in response to platelet-derived growth factor. Biochem J 320:123-127.
25. Ross R (1995) Cell biology of atherosclerosis. Annu Rev Physiol 57:791-804.
26. Schwartz SM, deBlois D, and O'Brien ERM (1995) The intima: soil for atherosclerosis and restenosis. Circ Res 77:445-465.
27. Shi Y, Hutchinson HG, Hall DJ, and Zalewski A (1994) Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation 90:1190-1195.
28. Simons M, Edelman ER, DeKeyser J-L, Langer R, and Rosenberg RD (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (Lond) 359:67-70.
29. Storm SM, Cleveland JL, and Rapp UR (1990) Expression of raf family protooncogenes in normal tissues. Oncogene 5:345-351.
30. Sun H, Tonks NK, and Bar-Sagi D (1994) Inhibition of Ras-induced DNA synthesis by expression of the phosphatase MKP-1. Science (Washington D C) 266:285-288.
31. Tuite MF (1996) Death by decapitation for mRNA. Nature (Lond) 382:577-579.
32. Verheij M, Bose R, Lin XH, Yao B, Jarvis DW, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z, and Kolesnick RN (1996) Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature (Lond) 380:75-79.
33. Wagner RW, Matteucci MD, Lewis JG, Gutierrez AJ, Moulds C, and Froehler BC (1993) Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science (Washington DC) 260:1510-1513.
34. Wu X, Noh SJ, Zhou G, Dixon JE, and Guan K-L (1996) Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated HeLa cells. J Biol Chem 271:3265-3271.
35. Xia Z, Dickens M, Raingeaud J, Davis RJ, and Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (Washington DC) 270: 1326-1331.